P.M. Phal
R.W.T. Myall
L.A. Assael
J.L. Weissman

Imaging Findings of Bisphosphonate-Associated Osteonecrosis of the Jaws

BACKGROUND AND PURPOSE: Bisphosphonates are drugs that decrease bone turnover by inhibiting osteoclast activity. An association between the use of bisphosphonates and osteonecrosis of the maxilla and mandible has recently been described. This study describes the imaging findings of bisphosphonate-associated osteonecrosis of the jaws.

MATERIALS AND METHODS: This is a retrospective series of 15 clinically diagnosed patients, identified at 3 centers. Eleven patients were women, of whom 6 had breast cancer, 3 had osteoporosis, and 2 had multiple myeloma. Of the 4 male patients, 2 had prostate cancer, 1 had multiple myeloma, and 1 had osteoporosis. The age range of the patients was 52–85 years (average, 68 years). The mandible was the clinical site of involvement in 11 patients, and the maxilla was involved in 4 patients. Imaging consisted of orthopantomograms in 14 patients, CT scans in 5 patients, and radionuclide bone scan in 1 patient. Nine patients had sequential imaging. Two radiologists reviewed the images.

RESULTS: All of the patients had a degree of osseous sclerosis, most commonly involving the alveolar margin, but lamina dura thickening and full-thickness sclerosis were also observed. The sclerotic change encroached on the mandibular canal in 3 patients. Less commonly encountered findings included poorly healing or nonhealing extraction sockets, periapical lucencies, widening of the periodontal ligament space, osteolysis, sequestra, oroantral fistula, soft tissue thickening, and periosteal new bone formation.

CONCLUSIONS: The most common finding in bisphosphonate-associated osteonecrosis was osseous sclerosis. This varied from subtle thickening of the lamina dura and alveolar crest to attenuated osteopetrosis-like sclerosis.

Bisphosphonates, drugs that decrease bone turnover by inhibiting osteoclast-mediated bone resorption, are used to treat osteoporosis, Paget disease, pain from osseous metastases, and malignancy-related hypercalcemia.¹ Recently osteonecrosis of the jaws has been associated with the use of bisphosphonates.^{2–8} Patients with bisphosphonate-associated osteonecrosis present with nonhealing extraction sockets and painful bone exposure.^{3,4} Because of the increasing use of bisphosphonates, these complications are now being encountered more frequently. Diagnosis of bisphosphonate-associated osteonecrosis is clinical, because it is preferable to avoid biopsy in patients taking bisphosphonates because of problems with healing postsurgical intervention.⁹ As a result, radiology is likely to play an increasing role in confirming the diagnosis. This study describes the imaging findings of bisphosphonate-associated osteonecrosis of the jaws.

Materials and Methods

Institutional review board permission was granted for this retrospective study of 15 patients taking bisphosphonates who developed osteonecrosis of the jaws that was diagnosed clinically. Patients included in this study were those currently receiving bisphosphonate therapy who developed painful dental conditions requiring management by

an oral and maxillofacial surgeon. This included patients with painful bone exposure, nonhealing extraction sockets, and infection difficult to manage with conventional therapy. The patients were identified at 3 centers. A chart review was performed to document the clinical details. Two radiologists reviewed the imaging of the jaws in consensus, which consisted of orthopantomograms in 14 patients, CT scans in 5 patients, and radionuclide bone scan in 1 patient. Nine patients had sequential imaging.

Eleven patients were women, of whom 6 had breast cancer, 3 had osteoporosis, and 2 had multiple myeloma. Of the 4 male patients, 2 had prostate cancer, 1 had multiple myeloma, and 1 had osteoporosis. The age range of the patients (at the time first seen by oral and maxillofacial surgeon) was 52–85 years (average, 68 years). The mandible was the clinical site of involvement in 11 patients, and the maxilla was involved in 4 patients.

Results

Clinical data from the 15 patients are shown in Table 1. Diagrams of normal orthopantomogram appearance and mild and advanced bisphosphonate-associated osteonecrosis are shown in Fig 1A–C. All of the patients in our study (15 patients) had a degree of osseous sclerosis, most commonly involving the alveolar margin (10 patients; Fig 2), but lamina dura thickening (7 patients) and full-thickness sclerosis (6 patients) were also observed (Figs 3 and 4). The sclerotic change encroached on the mandibular (inferior alveolar) canal in 3 patients. Five patients had poorly healing or nonhealing extraction sockets and periapical lucencies. Four patients had widening of the periodontal ligament space and osteolysis (Fig 5), 3 patients had sequestra (Fig 6), and 2 patients had oroantral fistula. Single patients had soft tissue thickening and periosteal new bone formation. The frequency of radiographic findings is shown in Table 2. The single patient in our series

Received July 9, 2006; accepted after revision September 23.

From the Division of Neuroradiology (P.M.P., J.L.W.), Department of Oral and Maxillofacial Surgery, School of Dentistry (R.W.T.M., L.A.A.), Department of Otolaryngology (J.L.W.), and Department of Ophthalmology (J.L.W.), Oregon Health and Science University, Portland, Ore.

Paper presented at: Annual Meeting of the American Society of Neuroradiology, May 3, 2006; San Diego, Calif.

Address correspondence to Pramit M. Phal, Department of Radiology, The Royal Melbourne Hospital, c/o Post Office, Parkville, Vic 3050, Australia; e-mail: pphal@iprimus.com.au

DOI 10.3174/ajnr.A0518

Table 1: Patient data

Patient	Age, years	Sex	Underlying Condition	Presentation	Location	Bisphosphonate	Biopsy	Management
1	65	F	Multiple myeloma	Nonhealing extraction socket; necrotic bone	Left maxilla	Zoledronate	Necrotic bone	Curettage, antibiotics, hyperbaric oxygen therapy
2	67	F	Metastatic breast cancer	Pain; nonhealing extraction socket	Right posterior mandible	Pamidronate changed to zoledronate	Not done	Analgesia; antibiotics
3	60	F	Metastatic breast cancer	Nonhealing extraction site; later complicated by infection and fistula formation	Left posterior mandible, third molar	Pamidronate	Chronic osteomyelitis	Curettage; antibiotic therapy
4	77	F	Multiple myeloma	Multifocal exposed bone	Bilateral body and symphysis of mandible	Pamidronate changed to zoledronate	Osteonecrosis, extensive bacterial infiltration (Fig 5C)	Mouth wash, antibiotics, surgical debridement
5	64	M	Multiple myeloma	Chronic nasal infection/sinusitis; pain	Central maxilla	Clodronate and pamidronate in the past	Not done	Long-term antibiotics
6	61	M	Metastatic prostate cancer	Painful bone exposure; subsequent loosening of teeth and spontaneous sequestration of the left mandible	Bilateral mandibular bodies	Zoledronate	Not done	Mouth rinses, antibiotics; filing of sharp bone spicule; removal of sequestra; extraction of tooth
7	75	F	Metastatic breast cancer	Infection, subcutaneous fistula; painful bone exposure	Initially anterior mandible, subsequently bilateral mandibular bodies	Zoledronate	Active osteomyelitis	IV antibiotics, then oral; marginal mandibulectomy
8	52	F	Metastatic breast cancer	Nonhealing extraction socket; painful bone exposure	First left mandibular molar	Zoledronate	Sequestrum and chronically inflamed mucosa	Mouth rinses; antibiotics; analgesia; debridement of extraction site
9	79	M	Metastatic prostate cancer	Infection; pain	Right posterior mandible	Alendronate changed to an injectable bisphosphonate	Not done	Antibiotics; mouth rinses
10	54	F	Metastatic breast cancer	Pain	Anterior mandible	Zoledronate	Not done	None
11	82	F	Osteoporosis	Nonhealing extraction socket	Left maxilla	Alendronate	Necrotic bone coated with bacterial colonies	Antibiotics, debridement
12	70	F	Osteoporosis	Nonhealing extraction socket	Right posterior mandible	Alendronate	Not done	Curettage, antibiotics
13	85	F	Osteoporosis	Nonhealing extraction socket; infection	Left posterior mandible	Alendronate	Necrotic bone coated with bacteria	Curettage, antibiotics
14	74	M	Osteoporosis	Infected exposed bone; pain	Right posterior body of mandible	Alendronate	Not done	Antibiotics, mouth washes, incision and drainage
15	54	F	Metastatic breast cancer	Pain, swelling, exposed bone, loose teeth; palatonasal and palatoantral fistula, sinusitis	Maxilla, bilateral	Zoledronate, alendronate, and pamidronate in the past	Osteonecrosis and acute osteomyelitis, abundant bacteria associated with bone infiltration	Multiple dental extractions, bilateral subtotal maxillectomy; antibiotics

Note:—M indicates male; F, female.

Fig 1. Radiographic findings in bisphosphonate-associated osteonecrosis of the jaws.

A, Normal: the alveolar crest of the jaws is the cortical bone of the alveolar margin in between teeth and is continuous with the lamina dura around the root of the tooth. The 1- to 2-mm lucency between the root of the tooth and the lamina dura corresponds with the space for the periodontal ligament.

B, In our series, osseous sclerosis was most commonly involved in the alveolar margin and lamina dura. The sclerotic changes were often diffuse rather than localized to the area of clinical involvement.

C, In the patients with sequential imaging, the sclerotic changes were often progressive and may encroach on the mandibular canal. The sclerosis of the medullary cavity may be attenuated and reminiscent of osteopetrosis.

Fig 2. A 65-year-old woman (patient 1 in Table 1) with multiple myeloma treated with zoledronate presented with a nonhealing extraction socket in the left posterior maxilla (second and third molars, *black arrow*). The orthopantomogram demonstrates generalized sclerosis of the alveolar margin of the mandible (*white arrows*) and the maxilla to a lesser extent. There is also thickening of the lamina dura.

who had technetium Tc99m hydroxymethylene diphosphonate (Tc99m-HDP) bone scan imaging had 2 examinations separated by 3 years and demonstrated progressively increased radiotracer uptake around the extraction socket in the right posterior mandible.

Discussion

Normal bone is a dynamic organ with a balance between bone formation from osteoblasts and resorption via osteoclasts.¹⁰ Bisphosphonates are drugs that decrease bone resorption by inhibition of osteoclasts.¹ First-generation bisphosphonates, such as clodronate and etidronate, are oral agents and act by causing osteoclast death by inducing apoptosis.¹¹ The newer nitrogen-containing bisphosphonates include alendronate, risedronate, and the intravenously administered pamidronate and zoledronate. These have a higher potency and inhibit osteoclasts by targeting an enzyme in the cholesterol biosynthetic pathway called farnesyl diphosphate synthase.¹²

Bisphosphonate-associated osteonecrosis of the jaws is a newly recognized entity,⁸ and formal diagnostic criteria have yet to be defined. The diagnosis of this entity relies on a char-

acteristic clinical presentation of painful bone exposure (Fig 7), histologic evidence of osteonecrosis (defined as empty lacunae and calcified matrix/osteopetrotic change with or without bacterial invasion), the absence of any histologic evidence of neoplasm, and a history of use of bisphosphonates. However, the rigid application of these criteria poses a number of problems. First, cases of exposed bone are not always associated with pain. In addition, histologic confirmation of the diagnosis is not always possible, as a biopsy is often avoided because these patients have problems with healing. Hence, biopsy is recommended only when there is high clinical suspicion of metastasis.⁹ The diagnosis of osteonecrosis is, therefore, largely based on clinical criteria, with the key elements being an appropriate clinical presentation and bisphosphonate use. It should be noted that because the skeletal half-life of bisphosphonates is more than 10 years,¹ it is possible that complications may occur after cessation of therapy.

The exact mechanism by which bisphosphonates cause osteonecrosis of the jaws is unclear. Most of the current theories are extrapolated from the known mechanisms of action of bisphosphonates and cases of osteonecrosis of the jaws that have occurred in association with bisphosphonate use.³⁻⁷ The metabolic theory is based on an altered balance between the actions of osteoclasts and osteoblasts.¹³ The effect is similar to that in osteopetrosis, a heterogeneous group of inherited conditions in which there is defect in bone resorption by osteoclasts.¹⁰ In support of this theory is the report of a child treated with bisphosphonates, albeit at a greater-than-recommended dose, that led to a generalized osteopetrosis-like state.¹⁴ In addition, the clinical effect of osteopetrosis on the jaws is similar to that of bisphosphonates, with osteopetrotic patients prone to problems with healing and infection of the jaws after dental procedures.^{15,16}

The antivascular theory is based on the known antiangiogenic effects of bisphosphonates that have been documented both in vitro and in vivo.^{17,18} Against this theory is the finding that more potent antiangiogenic drugs do not cause osteonecrosis of the jaws⁴ and the presence of normal numbers of

Fig 3. A 67-year-old woman (patient 2) with metastatic breast cancer treated with pamidronate and later zoledronate presented with a nonhealing extraction socket.
A, The orthopantomogram demonstrates the nonhealing extraction socket in the right posterior mandible (*) with sclerosis in the adjacent body and ramus of the mandible (arrow) and generalized thickening of the lamina dura in the mandible (arrowhead) and maxilla.
B, Axial CT demonstrates the osseous sclerosis, as well as narrowing the mandibular canal (*), thin periosteal new bone anteriorly (arrow) and generalized thickening of the lamina dura in the mandible (arrowhead).
C, Tc99m-HDP bone scan demonstrates increased radiotracer uptake in the right hemimandible corresponding with the area of sclerosis, which had increased over the last 3 years.

blood vessels in histologic sections of bisphosphonate-associated osteonecrosis.¹³

The Wolf law¹⁹ states that bone remodeling occurs secondary to the forces applied to it. Because the mandible and maxilla are subject to strong occlusal forces transmitted by the teeth and periodontal ligaments, there is a high bone turnover, which predisposes the jaws to certain conditions. “Phossy jaw”^{13,20} is a condition historically described in match factory workers in the mid-1800s who were exposed to metabolically active white phosphorus. This resulted in a painful and disfiguring condition of the jaws, with superimposed infection leading to a 20% mortality rate in this preantibiotic era.²¹ The accumulation of phosphorous in the jaws in this condition was thought related to the high bone turnover. Likewise, as bisphosphonates inhibit osteoclasts, they decrease bone remodeling and predispose bone to accumulated microdamage,²² again with the jaws particularly susceptible due to the high bone turnover. Supporting this theory is that there has been only 1 case of bisphosphonate-associated osteonecrosis outside the oral cavity.²³

The most commonly encountered radiographic finding in our series was osseous sclerosis, which was present in all 15 of the patients to a variable extent. The normal radiographic appearance of the alveolar crest is of a sharply defined thin radiodense line that is continuous with the lamina dura around

the root of the tooth, also a thin, well-defined line. The 1- to 2-mm lucency between the root of the tooth and the lamina dura corresponds with the space for the periodontal ligament.²⁴ In our series, case subjects with mild involvement had sclerosis of the alveolar margin and thickening of the lamina dura. The changes were often diffuse rather than localized to the area of clinical involvement. More advanced case subjects had greater degrees of osseous sclerosis, which may be attenuated and reminiscent of osteopetrosis and may narrow the mandibular canal. In the case subjects with sequential imaging, the sclerotic changes were often progressive. The generalized nature of the sclerotic changes in the jaws in bisphosphonate-associated osteonecrosis helps to differentiate this entity from reactive sclerosis, which tends to be localized around inflammatory foci.

The less frequently encountered findings in our series, such as osteolysis, soft tissue swelling, periosteal new bone formation, periapical lucencies, oroantral fistula, and sequestra, are likely to correspond with the presence of infection. In our series, 7 of 8 patients who had histopathologic assessment of their disease had changes of osteomyelitis. Although the histopathology of these patients demonstrates osteomyelitis, it is important to note that the oral cavity offers a unique microbial environment in which exposed bone is immediately contaminated with oral flora. Thus, bacterial colonies, as well as in-

Fig 4. A 60-year-old woman (patient 3) with widely metastatic breast cancer treated with pamidronate presented with a nonhealing extraction site in the left posterior mandible. *A*, Orthopantomogram demonstrates the nonhealing extraction site in the left posterior mandible (*) and sclerosis of the left ramus and angle of the mandible (arrowhead). *B*, Orthopantomogram, 23 months later with intervening curettage, demonstrates disorganized bone formation in the extraction socket of the lower left third molar, progressive sclerosis of the left ramus, and angle of the mandible (arrow) with further encroachment on the left mandibular canal (arrowhead).

flammatory infiltrates, are ubiquitous in oral necrotic bone such that differentiation between osteonecrosis and osteomyelitis can be muddled by this peculiarity. Our findings suggest that the radiographic appearance of bisphosphonate-associated osteonecrosis is in part determined by the presence of superimposed infection. This may prove to be a useful form of radiologic classification and correlates with a staging system proposed by Ruggiero.²⁵ To our knowledge, there is little in the literature regarding imaging findings in bisphosphonate-associated osteonecrosis. Most authors describe lytic destructive changes, sequestra, and soft tissue swelling,^{3,7,26} though Marx et al⁴ refer to the entity as “bisphosphonate associated osteopetrosis,” making reference to sclerotic changes in the jaws.

The radiologic differential diagnosis for bisphosphonate-associated osteonecrosis includes chronic sclerosing osteomyelitis of the jaws,^{27,28} osteoradionecrosis, metastasis, and Paget disease. Chronic sclerosing osteomyelitis of the mandible has the radiologic hallmarks of periosteal new bone, sclerosis, osseous expansion, and sequestra²⁸ (Fig 8). Osteoradionecrosis occurs after radiation therapy to the oral cavity and is radiologically manifested by poorly defined destruction of the mandible²⁹ (Fig 9). Metastases to the jaws are uncommon and are most commonly found in the posterior reaches of the mandible. They are most frequently lytic lesions,³⁰ with exceptions being prostate and breast cancer metastases, which may be sclerotic (Fig 10). Paget disease is typically manifest by osseous expansion and coarsened trabeculae.

The main limitation of our study is the small number of patients. Larger numbers are required before generalizations can be made regarding the typical radiologic findings in

Fig 5. A 77-year-old woman (patient 4) with multiple myeloma initially treated with pamidronate and subsequently zoledronate.

A, The initial orthopantomogram demonstrates osseous sclerosis (arrow). *B*, Orthopantomogram 9 months later demonstrates lytic destruction of the mandible, most prominent in the left body of the mandible (arrow). Surgical debridement was performed. *C*, Photomicrograph at low power ($\times 40$) of the curettage specimen stained with hematoxylin-eosin demonstrates fragments of necrotic bone with empty lacunae (arrow). There is extensive infiltration with inflammatory cells with surface resorption of bone (arrowhead) and bacteria (*).

bisphosphonate-associated osteonecrosis. Another limitation in our study is the variability in imaging studies between patients, which makes it difficult to analyze the frequency of findings. CT is a more sensitive imaging technique compared with panoramic radiography; subsequently, findings such as soft tissue swelling, periosteal new bone, and sequestrum are easier to detect on CT and may not be seen on orthopantomography. Finally, because the clinical details were obtained from a chart review, some details, such as the length of time that subjects were treated with bisphosphonates, were not available.

Fig 6. A 64-year-old man (patient 5) with multiple myeloma treated with pamidronate and subsequently clodronate presented with sinusitis and chronic nasal infection. Axial CT demonstrates maxillary sclerosis, sequestrum (*arrow*), and mucosal thickening in the right maxillary sinus.

Table 2: Frequency of radiographic findings

Radiographic Finding	No. of Cases (<i>n</i> = 15)
Osseous sclerosis (any type)	15
Alveolar margin	10
Lamina dura thickening	7
Full thickness of bone	6
Periapical lucency	5
Poorly healing extraction socket	5
Osteolysis	4
Widened periodontal ligament space	4
Encroachment on the mandibular canal	3
Sequestrum	3
Oroantral fistula	2
Periosteal new bone	1
Soft tissue swelling	1

Fig 7. A 61-year-old man (patient 6) with metastatic prostate cancer treated with zoledronate presents with painful bone exposure of the right mandible (*arrow*).

Conclusions

In our study, the most common finding in bisphosphonate-associated osteonecrosis was osseous sclerosis. This varied from subtle thickening of the lamina dura and alveolar crest to

Fig 8. Coronal CT in a 7-year-old girl with sclerosing osteomyelitis demonstrates osseous sclerosis, remodelling, periosteal new bone (*arrowhead*), and soft tissue swelling (*arrow*).

Fig 9. Orthopantomogram demonstrates mixed sclerotic and lytic destruction and pathologic fracture of the left body of the mandible (*arrow*) secondary to radiation osteonecrosis.

Fig 10. Axial CT demonstrates mixed lytic and sclerotic (*arrow*) metastases in the mandible and cervical spine secondary to breast carcinoma. Note the cortical thinning related to the lytic lesions.

attenuated osteopetrosis-like sclerosis. It is important for radiologists to recognize this entity, because imaging is likely to play an increasing role in confirming the diagnosis, as there is a preference to avoid biopsy.

Acknowledgments

We acknowledge Drs. Robin Cassumbhoy and Bernard Lim for contributing patients to the series, Dr. Jeffery Stewart for the provision of histologic sections, and Scott Jeffs for medical illustration.

References

1. Sparidans RW, Twiss IM, Talbot S. **Bisphosphonates in bone diseases.** *Pharm World Sci* 1998;20:206–13
2. Marx RE. **Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic.** *J Oral Maxillofac Surg* 2003;61:1115–17
3. Ruggiero SL, Mehrotra B, Rosenberg TJ, et al. **Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases.** *J Oral Maxillofac Surg* 2004;62:527–34
4. Marx RE, Sawatari Y, Fortin M, et al. **Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment.** *J Oral Maxillofac Surg* 2005;63:1567–75
5. Migliorati CA, Schubert MM, Peterson DE, et al. **Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy.** *Cancer* 2005;104:83–93
6. Bagan JV, Murillo J, Jimenez Y, et al. **Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases.** *J Oral Pathol Med* 2005;34:120–23
7. Carneiro E, Vibhute P, Montazem A, et al. **Bisphosphonate-associated mandibular osteonecrosis.** *AJNR Am J Neuroradiol* 2006;27:1096–97
8. Kolata G. **Drug for bones is linked to jaw disease.** *New York Times* June 2, 2006;sect A:1
9. Novartis. **Expert Panel Recommendation for the Prevention, Diagnosis and Treatment of Osteonecrosis of the Jaw.** East Hanover, NJ: Novartis; 2005. Available at: http://www.fda.gov/OHRMS/DOCKETS/AC/05/briefing/2005-4095B2_02_12-Novartis-Zometa-App-11.pdf
10. Tolar J, Teitelbaum SL, Orchard PJ. **Osteopetrosis.** *N Engl J Med* 2004;351:2839–49
11. Reszka AA, Rodan GA. **Mechanism of action of bisphosphonates.** *Curr Osteoporos Rep* 2003;1:45–52
12. Reszka AA, Rodan GA. **Nitrogen-containing bisphosphonate mechanism of action.** *Mini Rev Med Chem* 2004;4:711–19
13. Hellstein JW, Marek CL. **Bisphosphonate osteochemonecrosis (bis-phossy jaw): is this phossy jaw of the 21st century?** *J Oral Maxillofac Surg* 2005;63:682–89
14. Whyte MP, Wenkert D, Clements KL, et al. **Bisphosphonate-induced osteopetrosis.** *N Engl J Med* 2003;349:457–63
15. Junquera L, Rodriguez-Recio C, Villarreal P, et al. **Autosomal dominant osteopetrosis and maxillomandibular osteomyelitis.** *Am J Otolaryngol* 2005;26:275–78
16. Batra P, Shah N. **Recalcitrant osteomyelitis following tooth extraction in a case of malignant osteopetrosis.** *Int Dent J* 2004;54:418–23
17. Wood J, Bonjean K, Ruetz S, et al. **Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid.** *J Pharmacol Exp Ther* 2002;302:1055–61
18. Fournier P, Boissier S, Filleur S, et al. **Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats.** *Cancer Res* 2002;62:6538–44
19. Miesse AM, Willey JS, Bateman TA. **Potential role of proinflammatory cytokines in nerve damage related bone loss.** *Biomed Sci Instrum* 2004;40:266–71
20. Donoghue AM. **Bisphosphonates and osteonecrosis: analogy to phossy jaw.** *Med J Aust* 2005;183:163–64
21. Miles AE. **Phosphorus necrosis of the jaw: 'phossy jaw'.** *Br Dent J* 1972;133:203–06
22. Seeman E, Delmas PD. **Bone quality—the material and structural basis of bone strength and fragility.** *N Engl J Med* 2006;354:2250–61
23. Polizzotto MN, Cousins V, Schwarzer AP. **Bisphosphonate-associated osteonecrosis of the auditory canal.** *Br J Haematol* 2006;132:114
24. White S, Pharoah M. *Oral Radiology, Principles and Interpretation*, 4th ed. St. Louis: Mosby; 2000
25. Ruggiero SL. **Bisphosphonate-induced osteonecrosis: OMS perspective.** Paper presented at: Meeting of the American Association of Oral Maxillofacial Surgeons, 2005; Boston, September 20–25, 2005
26. Chiandussi S, Biasotto M, Dore F, et al. **Clinical and diagnostic imaging of bisphosphonate-associated osteonecrosis of the jaws.** *Dentomaxillofac Radiol* 2006;35:236–43
27. Hino S, Murase R, Terakado N, et al. **Response of diffuse sclerosing osteomyelitis of the mandible to alendronate: follow-up study by 99mTc scintigraphy.** *Int J Oral Maxillofac Surg* 2005;34:576–78
28. Orpe EC, Lee L, Pharoah MJ. **A radiological analysis of chronic sclerosing osteomyelitis of the mandible.** *Dentomaxillofac Radiol* 1996;25:125–29
29. Resnick D, Kransdorf M. *Bone and Joint Imaging*, 3rd ed. Philadelphia: Elsevier Saunders; 2005
30. van der Waal RI, Buter J, van der Waal I. **Oral metastases: report of 24 cases.** *Br J Oral Maxillofac Surg* 2003;41:3–6